Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases
Tóm tắt
Growing evidence suggests a prominent role of the complement system in the pathogenesis of cardio- and cerebrovascular diseases (CVD). Mannan-binding lectin-associated serine proteases (MASPs) MASP-1 and MASP-2 of the complement lectin pathway contribute to clot formation and may represent an important link between inflammation and thrombosis. MBL-associated protein MAp44 has shown cardioprotective effects in murine models. However, MAp44 has never been measured in patients with CVD and data on MASP levels in CVD are scarce. Our aim was to investigate for the first time plasma levels of MAp44 and MASP-1, -2, -3 concomitantly in patients with CVD. We performed a pilot study in 50 healthy volunteers, in stable coronary artery disease (CAD) patients with one-vessel (n = 51) or three-vessel disease (n = 53) and age-matched controls with normal coronary arteries (n = 53), 49 patients after myocardial infarction (MI) and 66 patients with acute ischaemic stroke. We measured MAp44 and MASP-1 levels by in-house time-resolved immunofluorometric assays. MASP-2 and MASP-3 levels were measured using commercial enzyme-linked immunosorbent assay kits. MASP-1 levels were highest in subacute MI patients and lowest in acute stroke patients. MASP-2 levels were lower in MI and stroke patients compared with controls and CAD patients. MASP-3 and MAp44 levels did not differ between groups. MASP or MAp44 levels were not associated with severity of disease. MASP and MAp44 levels were associated with cardiovascular risk factors including dyslipidaemia, obesity and hypertension. Our results suggest that MASP levels may be altered in vascular diseases. Larger studies are needed to confirm our results and elucidate the underlying mechanisms.
Từ khóa
Tài liệu tham khảo
Libby, 2009, Inflammation in atherosclerosis, J Am Coll Cardiol, 54, 2129, 10.1016/j.jacc.2009.09.009
Carter, 2005, Inflammation, thrombosis and acute coronary syndromes, Diab Vasc Dis Res, 2, 113, 10.3132/dvdr.2005.018
Oksjoki, 2007, Function and regulation of the complement system in cardiovascular diseases, Front Biosci, 12, 4696, 10.2741/2419
Speidl, 2011, Complement in atherosclerosis: friend or foe?, J Thromb Haemost, 9, 428, 10.1111/j.1538-7836.2010.04172.x
Frauenknecht, 2012, Complement – a phylogenetically old system as a new player in the development of atherosclerosis [in German], Hämostaseologie, 32, 276, 10.5482/ha-1191
Banz, 2012, Role of complement and perspectives for intervention in ischemia-reperfusion damage, Ann Med, 44, 205, 10.3109/07853890.2010.535556
Markiewski, 2007, Complement and coagulation: strangers or partners in crime?, Trends Immunol, 28, 184, 10.1016/j.it.2007.02.006
Amara, 2010, Molecular intercommunication between the complement and coagulation systems, J Immunol, 185, 5628, 10.4049/jimmunol.0903678
Ricklin, 2010, Complement: a key system for immune surveillance and homeostasis, Nat Immunol, 11, 785, 10.1038/ni.1923
Hansen, 2010, Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity, J Immunol, 185, 6096, 10.4049/jimmunol.1002185
Yongqing, 2012, Mannose-binding lectin serine proteases and associated proteins of the lectin pathway of complement: two genes, five proteins and many functions?, Biochim Biophys Acta, 1824, 253, 10.1016/j.bbapap.2011.05.021
Degn, 2011, Disease-causing mutations in genes of the complement system, Am J Hum Genet, 88, 689, 10.1016/j.ajhg.2011.05.011
Kidmose, 2012, Structural basis for activation of the complement system by C4 cleavage, Proc Natl Acad Sci USA, 109, 15425, 10.1073/pnas.1208031109
Degn, 2012, Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function, J Immunol, 189, 3957, 10.4049/jimmunol.1201736
Héja, 2012, Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2, Proc Natl Acad Sci USA, 109, 10498, 10.1073/pnas.1202588109
Sirmaci, 2010, MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes, Am J Hum Genet, 87, 679, 10.1016/j.ajhg.2010.09.018
Rooryck, 2011, Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome, Nat Genet, 43, 197, 10.1038/ng.757
Skjoedt, 2010, MBL-associated serine protease-3 circulates in high serum concentrations predominantly in complex with ficolin-3 and regulates ficolin-3 mediated complement activation, Immunobiology, 215, 921, 10.1016/j.imbio.2009.10.006
Dahl, 2001, MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway, Immunity, 15, 127, 10.1016/S1074-7613(01)00161-3
Iwaki, 2011, The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway, J Immunol, 187, 3751, 10.4049/jimmunol.1100280
Degn, 2009, MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation, J Immunol, 183, 7371, 10.4049/jimmunol.0902388
Skjoedt, 2012, Crystal structure and functional characterization of the complement regulator mannose-binding lectin (MBL)/ficolin-associated protein-1 (MAP-1), J Biol Chem, 287, 32913, 10.1074/jbc.M112.386680
Pavlov, 2012, Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis, Circulation, 126, 2227, 10.1161/CIRCULATIONAHA.112.123968
Hajela, 2002, The biological functions of MBL-associated serine proteases (MASPs), Immunobiology, 205, 467, 10.1078/0171-2985-00147
Krarup, 2007, Simultaneous activation of complement and coagulation by MBL-associated serine protease 2, PLoS ONE, 2, e623, 10.1371/journal.pone.0000623
Krarup, 2008, The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen, Biochim Biophys Acta, 1784, 1294, 10.1016/j.bbapap.2008.03.020
Gulla, 2010, Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot, Immunology, 129, 482, 10.1111/j.1365-2567.2009.03200.x
Hess, 2012, Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation, PLoS ONE, 7, e35690, 10.1371/journal.pone.0035690
La Bonte, 2012, Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis, J Immunol, 188, 885, 10.4049/jimmunol.1102916
Trendelenburg, 2010, Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention, Eur Heart J, 31, 1181, 10.1093/eurheartj/ehp597
Osthoff, 2011, Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients, PLoS ONE, 6, e21338, 10.1371/journal.pone.0021338
Mellbin, 2012, Complement activation and prognosis in patients with type 2 diabetes and myocardical infarction, Diabetes Care, 35, 911, 10.2337/dc11-1642
Zhang, 2011, MASP-2 activation is involved in ischemia-related necrotic myocardial injury, Int J Cardiol, 10.1016/j.ijcard.2011.11.032
Cervera, 2010, Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke, PLoS ONE, 5, e8433, 10.1371/journal.pone.0008433
Schroeder, 2002, Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography, Thromb Haemost, 88, 1020, 10.1055/s-0037-1613349
Schroeder, 2010, Coagulation factor XIII activation peptide and subunit levels in patients with acute ischemic stroke: a pilot study, Thromb Res, 126, e122, 10.1016/j.thromres.2010.05.027
Brott, 1989, Measurements of acute cerebral infarction: a clinical examination scale, Stroke, 20, 864, 10.1161/01.STR.20.7.864
Adams, 1993, Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment, Stroke, 24, 35, 10.1161/01.STR.24.1.35
Degn, 2010, Biological variations of MASP-3 and MAp44, two splice products of the MASP1 gene involved in regulation of the complement system, J Immunol Methods, 361, 37, 10.1016/j.jim.2010.07.006
Thiel, 2012, Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1), a serine protease associated with humoral pattern-recognition molecules: normal and acute-phase levels in serum and stoichiometry of lectin pathway components, Clin Exp Immunol, 169, 38, 10.1111/j.1365-2249.2012.04584.x
Schwaeble, 2011, Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury, Proc Natl Acad Sci USA, 108, 7523, 10.1073/pnas.1101748108
Orsini, 2012, Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia, Circulation, 126, 1484, 10.1161/CIRCULATIONAHA.112.103051
Møller-Kristensen, 2003, Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals, J Immunol Methods, 282, 159, 10.1016/j.jim.2003.08.012
Ytting, 2007, Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise, Scand J Immunol, 66, 458, 10.1111/j.1365-3083.2007.01991.x
Kohler, 2002, Insulin resistance syndrome: interaction with coagulation and fibrinolysis, Swiss Med Wkly, 132, 241
Cortesio, 2006, Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5, Arch Biochem Biophys, 449, 164, 10.1016/j.abb.2006.02.006
Fischer, 2004, Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease, Clin Endocrinol (Oxf), 61, 595, 10.1111/j.1365-2265.2004.02136.x